A new study suggests that GLP-1 medications, the class of drugs that includes semaglutide and has transformed treatment for obesity and type 2 diabetes, may eventually be prescribed based on a patient's individual biological profile rather than as a one-size-fits-all treatment. Researchers found meaningful differences in how patients respond to different drugs within the GLP-1 class, raising the possibility that matching a specific drug to a specific patient could improve outcomes.
According to a report by FOX8 WGHP, the study examined variation in patient responses to GLP-1 receptor agonists and found that factors including genetics and metabolic differences influence how well a given drug works for a given person. The findings point toward a future in which doctors might use biological markers to select the most effective GLP-1 drug for each patient before starting treatment, rather than switching medications after an initial option fails to produce results.
GLP-1 stands for glucagon-like peptide-1, a hormone the body produces naturally in the gut after eating. The drugs in this class mimic that hormone, signaling the brain to reduce appetite, slowing the movement of food through the stomach, and affecting insulin release. Semaglutide, sold under the brand names Ozempic and Wegovy, is among the best known, but other drugs in the class include tirzepatide, liraglutide, and dulaglutide, each with slightly different mechanisms and dosing structures.
The commercial success of GLP-1 drugs has been extraordinary. Demand has outpaced supply at various points since semaglutide gained wide attention for its weight loss effects, and the drugs have generated tens of billions of dollars in revenue for their manufacturers. Despite that commercial dominance, questions remain about why some patients lose significant weight while others see modest results on the same medication at the same dose.
The study's findings suggest that biology, not just behavior or adherence, may explain some of that variation. If researchers can identify which biological markers predict a stronger response to a particular drug, clinicians could theoretically use a simple test to guide the initial prescription decision. That approach mirrors personalized medicine strategies already used in oncology, where tumor genetics are used to match cancer patients with targeted therapies.
The practical application of that approach in GLP-1 prescribing is still some distance away. Identifying reliable biomarkers requires validation across large and diverse patient populations, and any test used to guide prescribing would itself need regulatory approval. The study reported by FOX8 WGHP represents an early step in that direction rather than a clinical tool ready for immediate use.
Cost and access are also factors in the GLP-1 landscape. The drugs remain expensive, and insurance coverage is inconsistent. Many patients who could benefit medically from GLP-1 treatment cannot afford it or cannot find a provider who will prescribe it. Personalizing treatment would add another layer of complexity to an already fragmented access picture, though proponents argue that getting the right drug to the right patient sooner could ultimately reduce the costs associated with treatment failure and medication switching.
The research adds to a growing body of work aimed at understanding why GLP-1 drugs produce such different results across patients and whether those differences can be predicted and acted upon before treatment begins.
